NCT01474681 - Safety and Tolerability of HSC835 in Patients With Hematological Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 9, 2012

Primary Completion Date

October 3, 2016

Study Completion Date

October 3, 2016

Conditions

Acute Myelocytic LeukemiaAcute Lymphocytic LeukemiaChronic Myelogenous LeukemiaMyelodysplastic SyndromeChronic Lymphocytic LeukemiaMarginal Zone LymphomaFollicular LymphomasLarge-cell LymphomaLymphoblastic LymphomaBurkitt's LymphomaHigh Grade LymphomasMantle-cell LymphomaLymphoplasmacytic Lymphoma

Interventions

BIOLOGICAL

HSC835

Trial Locations (1)

55455

Novartis Investigative Site, Minneapolis